Key result
Treatment of in-stent restenosis with paclitaxel-eluting stents resulted in a 29% major adverse cardiac event rate and a mean late loss of 0.54 mm, with no subacute stent thrombosis at 12 months.
Why the study?
Is paclitaxel-eluting stent implantation safe and feasible for the treatment of in-stent restenosis?
Population
28 patients with in-stent restenosis meeting criteria of lesion length <=30 mm, 50% to 99% diameter…
Design
Cohort
Follow-up
up to 12 months
Authors
Discussion
Loading...
Member takes
Implication
Paclitaxel-eluting stents may be feasible for in-stent restenosis; leaves open need for randomized confirmation before practice change.
Study Design
Type
Observational (n=28)
Multicenter
Yes
Structured PICO
Is paclitaxel-eluting stent implantation safe and feasible for the treatment of in-stent restenosis?
P
Population
28 patients with in-stent restenosis (ISR) meeting criteria of lesion length <=30 mm, 50% to 99% diameter stenosis, and vessel diameter 3.0 to 3.5 mm.
I
Intervention
TAXUS NIRx paclitaxel-eluting stents (one or more)
O
Outcome
Feasibility and safetysafety
Paclitaxel-eluting stents show potential safety and efficacy for treating in-stent restenosis, with IVUS guidance recommended to optimize deployment and reduce reintervention.
Cite This Study
Tanabe et al. (2003) conducted an observational in In-stent restenosis (ISR) (n=28). TAXUS NIRx paclitaxel-eluting stents was evaluated on Major adverse cardiac event rate. Treatment of in-stent restenosis with paclitaxel-eluting stents resulted in a 29% major adverse cardiac event rate and a mean late loss of 0.54 mm, with no subacute stent thrombosis at 12 months.